VASOCIDIN
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
Aug 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VASOCIDIN is a small-molecule ophthalmic solution approved in 1988 for eye care indications. The generic mechanism of action and specific indications are not currently documented. It is administered topically as eye drops for treating ocular conditions.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), indicating a mature asset with likely reduced team investment and career growth potential.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VASOCIDIN offers limited career advancement opportunities given its mature lifecycle status and approaching loss of exclusivity. Roles are primarily focused on defensive commercialization and market maintenance rather than growth or innovation.
Brand ManagerField Sales Representative
Worked on VASOCIDIN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.